Skip to the story
All StoriesPoliticsConflict & SecurityBusiness & EconomyScience & TechHealthClimateMedia
All stories
Health402 outlets ran this4 min read

Moderna and Merck report melanoma vaccine trial success in phase three

Personalised mRNA shot combined with Keytruda extended time without cancer returning in over 1,100 patients

AI-assisted coverage comparison, editor-supervised · How this was made

Published Updated
Moderna and Merck report melanoma vaccine trial success in phase three

What this story says

  • The phase three trial tested a personalised mRNA cancer vaccine combined with Merck’s Keytruda in over 1,100 melanoma patients after surgical removal of their cancer.
  • The treatment met its primary goal, extending the time patients lived without melanoma returning compared with Keytruda alone, and reduced the risk of distant spread.
  • Moderna’s stock rose over 10% and Merck’s by more than 1% following the announcement, reflecting investor expectations for the therapy’s potential.
  • The companies plan to present full data at an upcoming medical meeting but have not yet disclosed when they will seek regulatory approval.

Who covered it

Left 22%(61)Centre 56%(153)Right 22%(60)

Percentages are shares of the 274 outlets carrying a published leaning rating. 128 of the 402 outlets we know ran this story carry no rating and are not counted in them. Coverage measured .

Trust

85/100

Craft

85/100

Hype

15/100

402 sources · methodology

Merck and Moderna announced on 19 August 2026 that their personalised mRNA cancer vaccine, combined with Merck’s immunotherapy drug Keytruda, met the primary goal of a phase three trial in patients with high-risk or advanced melanoma. The trial involved more than 1,100 participants whose cancer had been surgically removed. The combination treatment extended the time patients lived without melanoma returning compared with Keytruda alone, and reduced the risk of the cancer spreading to distant parts of the body.

The companies reported the results in a joint statement. Merck’s shares rose more than 1% in premarket trading, while Moderna’s stock jumped over 10%. The trial’s secondary outcomes, including overall survival, are still being assessed. The drugmakers plan to present the full data at an upcoming international medical meeting but have not specified when they will submit applications for regulatory approval in the United States.

The vaccine is designed to target the unique mutations in each patient’s tumour, training the immune system to recognise and attack those markers. Keytruda, already a standard treatment for melanoma, is used to enhance the immune response. Side effects were reported to be similar to those of other vaccines. The trial’s success marks the first positive late-stage results for an mRNA cancer vaccine.

What the coverage left out

None of the digests from the centre-rated or right-rated outlets mentioned the planned presentation of full data at an upcoming medical meeting. The CNBC report, the only full article in the material, was the only one to include details about the vaccine’s personalised mechanism, the side effects, or the broader implications for other cancer types.

Tags:#CancerResearch#MelanomaTreatment#MRNAVaccines#ClinicalTrials#Pharmaceuticals

Coverage settled. We checked this 299 times and stopped on 24 Aug 2026, 18:00. The figures above are what it finished at.

How each side covered it

Our own reading of the reporting listed below, written from the outlets’ articles rather than quoted from them. The reasoning is set out on our methodology page.

Left

61 rated outlets

  • CNBC led its report with the trial meeting its primary goal of extending the time patients lived without melanoma returning. It quoted Dr. Jane Healy, Merck’s head of oncology early development, who called the results "very exciting" and noted the treatment’s "clinically meaningful improvement" over Keytruda alone. The report also highlighted the personalised approach of the vaccine, describing how it targets unique tumour mutations, and included analyst expectations that the results could validate Moderna’s broader cancer vaccine strategy.

Centre

153 rated outlets

  • The three centre-rated digests, from the Wall Street Journal, STAT, and Reuters, all led on the trial’s success in preventing melanoma from returning or spreading. The Wall Street Journal’s digest framed the results as paving the way for a "potentially new life-extending treatment" for melanoma patients. STAT’s digest noted the vaccine’s effect in slowing both recurrence and distant spread. Reuters’ digest described the trial as the first positive late-stage results for an mRNA cancer vaccine, emphasising the reduction in recurrence and spread compared with Keytruda alone.

Right

60 rated outlets

  • All four right-rated digests report that Moderna and Merck’s mRNA-based melanoma vaccine succeeded in a phase-three trial. They agree the trial met its primary goal of reducing the risk of melanoma returning or death in patients who had high-risk tumours removed.
  • Three digests lead on the share-price reaction. Seeking Alpha and Zero Hedge both note Moderna’s premarket surge, with Zero Hedge quoting an 83 % gain. The News and ussanews.com instead lead on the trial’s status as the first late-stage success for a personalised cancer vaccine.
  • None of the digests mention the absolute risk reduction, the number of patients enrolled, or the median follow-up period. Zero Hedge is the only digest to name the vaccine (mRNA-4157/V940) and to specify that the trial combined the vaccine with Merck’s Keytruda.

Questions about this coverage

How did the left and right cover Moderna and Merck report melanoma vaccine trial success in phase three?
Of the 274 outlets on this story carrying a published leaning rating, 22% are rated left, 56% are rated centre, 22% are rated right. Those percentages are shares of the rated outlets, not of every outlet that ran it, which was 402. The sections above set out what each side emphasised, in its own terms.
Is Moderna and Merck report melanoma vaccine trial success in phase three left or right?
Neither side dominates it. Of the 274 rated outlets on this story, 22% are rated left, 56% are rated centre, 22% are rated right, and no side holds the 70% this site would want before calling a field one-sided. A story is not left or right in any case; the outlets that carried it are what carry ratings.
Is the coverage of Moderna and Merck report melanoma vaccine trial success in phase three biased?
Moderna and Merck report melanoma vaccine trial success in phase three is one event reported by 402 outlets, and this page does not rate the story as biased or unbiased. What it publishes is the spread: which outlets ran it, where named rating organisations place each of them on the spectrum, and what each side chose to lead with. A leaning rating describes an outlet's record over time, not this article, and the two should not be run together.
Which outlets covered Moderna and Merck report melanoma vaccine trial success in phase three?
402 that we know of, every one of them listed further up this page with a link to its own report and to what we hold on the publisher. Nothing here is a summary of somebody else's summary: the outlets are named so the original reporting can be read.
What did the melanoma vaccine trial achieve?
The phase three trial found that a personalised mRNA cancer vaccine combined with Keytruda extended the time patients lived without melanoma returning and reduced the risk of the cancer spreading. The results mark the first successful late-stage trial for an mRNA cancer vaccine, with further data to be presented at a medical meeting.
How many patients were in the melanoma vaccine trial?
The trial included more than 1,100 patients with higher-risk or advanced melanoma whose cancer had been surgically removed. The combination treatment was compared with Keytruda alone to assess its effectiveness in preventing recurrence and spread.
When will the melanoma vaccine be available?
Merck and Moderna have not disclosed when they will submit applications for regulatory approval in the U.S. The companies plan to present full data at an upcoming international medical meeting, but the timeline for approval remains unclear.

Read it at the source

406 outlets, grouped by the leaning a published rating gives them. Every headline links to the original; an underlined outlet name opens our profile of that publisher.

Left

62
Show 54 more

Centre

154
Show 146 more

Right

61
Show 53 more

Not rated

129
Show 121 more

How did this read?

About the coverage, not about the story. We do not ask whether you agree with what happened — we have no honest use for that answer.

More in Health

All Health →
Firma lui Ianis Hagi se extinde spre imobiliare. Activele imobilizate au trecut de 2 milioane EUR3 min readGlobal life expectancy nears pre-pandemic levels, WHO reportsRead storyTrifluoroacetic acid found in blood of all 110 European study volunteers4 min readTrifluoroacetic acid found in blood of all 110 European study volunteersRead storyPhoto of a medical worker preparing to administer a flu shot3 min readNHS offers free flu jabs to homeless people for first timeRead story

Elsewhere on the site

Bayer to build $2.2bn Ohio plant creating 600 jobsBusiness & Economy•3 min readBayer to build $2.2bn Ohio plant creating 600 jobsFlorida sues Pfizer over COVID-19 vaccine marketingPolitics•3 min readFlorida sues Pfizer over COVID-19 vaccine marketingKim Yo-jong, sister of North Korea's leader Kim Jong-un, attends a wreath laying ceremony at Ho Chi Minh Mausoleum in Hanoi, March 2, 2019. AFP-YonhapConflict & Security•3 min readNorth Korea fires strategic missile with AI, sister saysSea levels to rise on West Coast; voters dissatisfied with partiesPolitics•3 min readSea levels to rise on West Coast; voters dissatisfied with parties
Moderna and Merck report melanoma vaccine trial success in phase three | MediaBias News